A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis
Status:
Completed
Trial end date:
2018-04-20
Target enrollment:
Participant gender:
Summary
This study seeks to evaluate the safety, tolerability, pharmacokinetics (PK) and
immunogenicity of ABT-555 in participants with relapsing forms of multiple sclerosis (RFMS).